# Synthesis, Structural and Pharmacological Characterizations of CIC, a Novel α-Conotoxin with an Extended N-Terminal Tail

Julien Giribaldi, Yves Haufe, Edward Evans, David Wilson, Norelle Daly, Christine Enjalbal, Annette Nicke, Sébastien Dutertre

► To cite this version:

Julien Giribaldi, Yves Haufe, Edward Evans, David Wilson, Norelle Daly, et al.. Synthesis, Structural and Pharmacological Characterizations of CIC, a Novel α-Conotoxin with an Extended N-Terminal Tail. Marine drugs, 2021, 19 (3), pp.141. 10.3390/md19030141. hal-03440279

HAL Id: hal-03440279

https://hal.science/hal-03440279

Submitted on 26 Aug 2022

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

Article

# Synthesis, Structural and Pharmacological Characterizations of CIC, a Novel α-Conotoxin with an Extended N-Terminal Tail

Julien Giribaldi<fnref n="1" />, Yves Haufe<fnref n="2" />, Edward R. J. Evans<fnref n="3" />, David T. Wilson<fnref n="3" />, Norelle L. Daly<fnref n="3" />, Christine Enjalbal<fnref n="1" />, Annette Nicke<fnref n="2" /> and Sébastien Dutertre<fnref n="1" />,*

<figure><img src="image_3.png" /></figure>

check for
updates

**Citation:** Giribaldi, J.; Haufe, Y.; Evans, E.R.J.; Wilson, D.T.; Daly, N.L.; Enjalbal, C.; Nicke, A.; Dutertre, S. Synthesis, Structural and Pharmacological Characterizations of CIC, a Novel α-Conotoxin with an Extended N-Terminal Tail. *Mar. Drugs* **2021**, *19*, 141. https://doi.org/10.3390/md19030141

Academic Editor:
Orazio Taglialatela-Scafati

Received: 29 January 2021
Accepted: 25 February 2021
Published: 2 March 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

<figure><img src="image_4.png" /></figure>

**Copyright:** © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

**Abstract:** Cone snails are venomous marine predators that rely on fast-acting venom to subdue their prey and defend against aggressors. The conotoxins produced in the venom gland are small disulfide-rich peptides with high affinity and selectivity for their pharmacological targets. A dominant group comprises α-conotoxins, targeting nicotinic acetylcholine receptors. Here, we report on the synthesis, structure determination and biological activity of a novel α-conotoxin, CIC, found in the predatory venom of the piscivorous species *Conus catus* and its truncated mutant Δ-CIC. CIC is a 4/7 α-conotoxin with an unusual extended N-terminal tail. High-resolution NMR spectroscopy shows a major influence of the N-terminal tail on the apparent rigidity of the three-dimensional structure of CIC compared to the more flexible Δ-CIC. Surprisingly, this effect on the structure does not alter the biological activity, since both peptides selectively inhibit α3β2 and α6/α3β2β3 nAChRs with almost identical sub- to low micromolar inhibition constants. Our results suggest that the N-terminal part of α-conotoxins can accommodate chemical modifications without affecting their pharmacology.

**Keywords:** conotoxin; peptide synthesis; NMR structure; electrophysiology; nicotinic acetylcholine receptors

## 1. Introduction

Conotoxins are short peptides (8 to 32 residues) highly constrained by disulfide bridges (1 to 4 disulfide bonds) found in predatory marine cone snail venoms [1]. Cone snails have evolved into more than 800 different species [2]; their fast-acting venom is composed of 100–200 different conotoxins and has been tailored for predation and defense purposes [3]. There is relatively low overlap between the toxins present within different cone snail species [4], and it is estimated that cone snail venoms may overall contain at least 70,000 mostly neuroactive peptides, of which less than 0.1% have currently been pharmacologically characterized [5]. Moreover, their small size, structural stability and target specificity are valuable assets that make them important pharmacological probes or even drug leads [6]. Based on their conserved signal sequence, conotoxins are grouped into various gene superfamilies and further classified according to their cysteine frameworks and their biological activity [5].

Members of the α-subfamily specifically target neuronal and muscle-type nicotinic acetylcholine receptors (nAChRs) [1]. In addition, a pattern is emerging based on the number of amino acids between the cysteine residues: 3/5 α-conotoxins are most likely to target muscle-type nAChRs, while 4/7 α-conotoxins target α7 and/or α3β2* neuronal nAChRs [7]. However, in most α-conotoxins, the number of residues outside the cysteine

<footnote n="1">¹ Institut des Biomolécules Max Mousseron, UMR 5247, Université de Montpellier, CNRS, ENSCM, 34095 Montpellier, France; julien.giribaldi@umontpellier.fr (J.G.); christine.enjalbal@umontpellier.fr (C.E.)</footnote>

<footnote n="2">² Walther Straub Institute of Pharmacology and Toxicology, Faculty of Medicine, LMU Munich, Nußbaumstraße 26, 80336 Munich, Germany; yves.haufe@lrz.uni-muenchen.de (Y.H.); annette.nicke@lrz.uni-muenchen.de (A.N.)</footnote>

<footnote n="3">³ Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD 4878, Australia; edwardrobertjonathan evans@my.jcu.edu.au (E.R.J.E.); david.wilson4@jcu.edu.au (D.T.W.); norelle.daly@jcu.edu.au (N.L.D.)</footnote>

<footnote>* Correspondence: sebastien.dutertre@umontpellier.fr</footnote>
loops is usually limited to one or two amino acids (Figure 1A). Based on Conoserver data [8,9], α-conotoxin GID is the only described 4/7 α-conotoxin showing a significant N-terminal extension (>2 residues) and is a potent blocker of α3β2 and α7 (low nanomolar IC₅₀) nAChRs, but also shows a significant and noteworthy inhibition of α4β2 nAChR subtypes (IC₅₀ 152 nM), which appear to be “α-conotoxin-resistant” receptors [1,10]. Considering the important role of α4 and β2 subunits in addiction, pain and cognition, which has been revealed by knockout studies [11], α4β2 nAChR-selective ligands would be very valuable pharmacological tools. Interestingly, deletion of the N-terminal sequence of GID (Δ-1-4) leads to loss of activity at the α4β2 subtype but has no effect on the IC₅₀ value at α3β2 and α7 subtypes (but affects the dissociation rate at these receptors). These findings suggest that the N-terminal residues are important for both selectivity and affinity [10]. However, despite these effects, the N-terminal tail of GID appears to be disordered in solution.

<figure><img src="image_5.png" /><figcaption>**Figure 1.** CIC alignment, UV chromatograms and ESI-MS analyses of synthetic peptides. (A). Alignment of CIC conotoxin with others closely related 4/7 α-conotoxins. The γ symbol indicates a carboxyglutamate residue, and O as a capital letter indicates a hydroxyproline residue. GID and CIC conotoxins are the only ones to display an N-terminal tail comprising more than two residues. The globular disulfide connectivity Cys I-III, Cys II-IV is represented. (B). RP-HPLC/ESI-MS analyses of synthetic Δ-CIC and CIC. ACN gradient was from 0 to 30% over 30 min. Reported mass values correspond to the average masses.</figcaption></figure>

Here, we describe a new α-conotoxin, CIC, which was previously found in the proteo-
transcriptomic study of *Conus catus* and identified as a component of the predation-evoked
venom [12]. The native CIC has never been isolated from the venom and tested nor its
sequence chemically synthesized. CIC shows high sequence similarity to PeIA and MII
α-conotoxins, both potent antagonists of α3β2 nAChR subtypes with IC₅₀ values in the low
nanomolar range [13,14]. However, unlike every other characterized 4/7 α-conotoxins, CIC
displays an extended N-terminal tail comprising six residues. Therefore, the aim of this
study was to investigate the role of this unusual N-terminal part on the three-dimensional
structure and on the pharmacological activity. To this end, native CIC conotoxin, as well
as a deletion variant with no N-terminal tail (Ala1-Thr6 removed) named Δ-CIC, were
synthesized and both pharmacologically and structurally characterized.
## 2. Results

### 2.1. Chemical Synthesis of CIC and Δ-CIC

CIC and Δ-CIC were synthesized manually using Fmoc-SPPS after anchoring of the first C-terminal residue on a chloro-(2'-chloro) trityl resin. Considering its sequence homology to other 4/7 α-conotoxins (Figure 1A), which all display the canonical globular disulfide bond connectivity CysI-CysIII, CysII-CysIV, linear peptides were folded using a regioselective folding strategy to obtain the globular isomer. Briefly, the first disulfide bridge (CysII-CysIV) is formed by oxidation of the free cysteine residues in an aqueous basic buffer assisted by DTP (2,2'-Dithiopyridine), and the second disulfide bond (CysI-CysIII) is formed by deprotection/oxidation of the Acm protecting groups [15]. The homogeneity of folded toxins was assessed by analytical RP-HPLC coupled to ESI-MS (Figure 1B). ESI-MS(+) confirmed a monoisotopic mass of 1602.90 g/mol (calculated 1602.59 g/mol) for Δ-CIC and 2106.27 g/mol (calculated 2106.29 g/mol) for CIC. Overall, 7.7 mg (yield 3.1% from resin loading) and 9.9 mg (yield 3.2% from resin loading) of pure (>95% based on LC/ESI-MS) Δ-CIC and CIC were obtained, respectively.

### 2.2. Electrophysiology of CIC and Δ-CIC on Neuronal nAChRs

α-conotoxins PeIA [13] and MII [14], which are closely related (based on the primary structure, Figure 1A) to CIC, are potent inhibitors of α3β2 nAChRs subtypes, while the N-terminally extended GID conotoxin inhibits α3β2, α7 and α4β2 nAChR subtypes (Table 1). The latter is also inhibited to a limited extent by MII. Because of these similarities, the antagonistic potency of CIC and Δ-CIC was firstly investigated using two-electrode voltage-clamp analysis on α3β2, α7, and α4β2 rat nAChRs subtypes. Whereas no inhibition was detected at the α7 and α4β2 subtypes, CIC and Δ-CIC inhibited the rat α3β2 neuronal nAChR subtype with rather high IC₅₀ values of 3.51 µM and 4.56 µM, respectively. At the closely related α6/α3β2β3 subtype, CIC and Δ-CIC showed IC₅₀ values of 0.94 µM and 1.00 µM, respectively (Figure 2, Table 1). Considering that these values are approximatively 1000-fold higher than those of the similar (based on sequence) α-conotoxin MII, we assumed major structural differences and also tested CIC and Δ-CIC on additional rat nAChRs such as α4β4, α3β4, α2β2, α2β4 and (α1)2β1δγ subtypes as well as human α9α10 subtype. It is noteworthy that no inhibition was detected at concentrations up to 10 µM on any of the additional nAChRs tested. In summary, despite some similarity to potent conotoxins, both CIC and Δ-CIC showed weak or no inhibition at common mammalian nAChR combinations (with no difference in dissociation behavior), and the quasi-identical values of inhibition constant between CIC and Δ-CIC at α3β2-containing nAChRs suggest that there is no major influence of the N-terminal tail on their affinity.

<table><caption>**Table 1.** IC₅₀ values of the conotoxins discussed in the text on the different nAChR subtypes. N.D means not determined.</caption><thead><tr><th rowspan="2">nAChR Subtypes</th><th colspan="4">Toxin (IC<sub>50</sub>)</th></tr><tr><th>CIC</th><th>Δ-CIC</th><th>MII</th><th>GID</th></tr></thead><tbody><tr><td>α3β2</td><td>3.51 µM</td><td>4.56 µM</td><td>3.7 nM</td><td>3.1 nM</td></tr><tr><td>α6/α3β2β3</td><td>1.03 µM</td><td>1.08 µM</td><td>390 pM</td><td>N.D</td></tr><tr><td>α7</td><td>>10 µM</td><td>>10 µM</td><td>200 nM (56% inhibition)</td><td>4.5 nM</td></tr><tr><td>α4β2</td><td>>10 µM</td><td>>10 µM</td><td>200 nM (30% inhibition)</td><td>152 nM</td></tr><tr><td>α4β4</td><td>>10 µM</td><td>>10 µM</td><td>200 nM (4% inhibition)</td><td>>5 µM</td></tr><tr><td>α3β4</td><td>>10 µM</td><td>>10 µM</td><td>200 nM (15% inhibition)</td><td>>5 µM</td></tr><tr><td>α2β2</td><td>>10 µM</td><td>>10 µM</td><td>200 nM (20% inhibition)</td><td>N.D</td></tr><tr><td>α2β4</td><td>>10 µM</td><td>>10 µM</td><td>200 nM (4% inhibition)</td><td>N.D</td></tr><tr><td>(α1)2β1δγ</td><td>>10 µM</td><td>>10 µM</td><td>200 nM (11% inhibition)</td><td>N.D</td></tr><tr><td>α9α10</td><td>>10 µM</td><td>>10 µM</td><td>>1 µM</td><td>N.D</td></tr><tr><td>References</td><td>This work</td><td>This work</td><td>[14,16–18]</td><td>[10]</td></tr></tbody></table>
<figure><img src="image_6.png" /><figcaption>**Figure 2.** Dose-response curves and representative current traces of CIC and Δ-CIC on rat α3β2 and α6/α3β2β3 nAChR subtypes expressed in *Xenopus laevis* oocytes. 2-Electrode voltage-clamp experiments were performed at −70 mV. Responses to 2-s pulses of 100 µM ACh (indicated by a black bar) were recorded after a 3-min preincubation with the indicated peptides. Each point represents the mean of measurements from at least 3 different oocytes. Error bars represent S.D. No effects were observed on α7, α4β2, α4β4, α3β4, α2β2, α2β4 and (α1)₂β1δγ rat subtypes as well as human α9α10 subtype at concentrations up to 10 µM.</figcaption></figure>

## 2.3. *Three-Dimensional Structure Determination of CIC and Δ-CIC*

High-resolution NMR spectroscopy allowed the determination of the three-dimensional structures of both CIC and Δ-CIC (Figure 3). The structure statistics are given in Table 2. The calculated structures of CIC are well-defined with an RMSD value over backbone atoms, excluding the N-terminal tail, of 0.29 ± 0.16 Å (residues 7–21). CIC exhibits two 3¹⁰ helices from residues Thr6 to Ser9 and Pro11 to Gln16. Interestingly the N-terminal tail displays a relatively well-defined structure. However, Δ-CIC lacks the first helix and has only one 3¹⁰ helix from residues Pro5 to Val9, suggesting that the N-terminal tail plays a role in inducing the first helix. Counterintuitively, the calculated structures of Δ-CIC are less defined and display a higher RMSD value (2.06 ± 0.73 Å, over backbone atoms) than CIC, which indicates a stabilizing role of the N-terminal tail. Moreover, the lack of the N-terminal tail in Δ-CIC appears to change the overall structure, with the C-terminal region (Ser18-Cys21) in a different orientation with respect to the helix.
<figure><img src="image_7.png" /><figcaption>**Figure 3.** Three-dimensional structures of CIC and Δ-CIC. The backbones are shown in ribbon format and the side-chains in stick format. Top panels. Superposed backbone atoms (ribbon representation) for the 20 lowest-energy NMR structures for CIC (left) and Δ-CIC (right). Lower panels. Ribbon and stick representation of the lowest energy state for CIC (left) and Δ-CIC (right).</figcaption></figure>

<table><caption>**Table 2.** Structural statistics for CIC and Δ-CIC.</caption><thead><tr><th>Experimental Restraints</th><th>CIC</th><th>Δ-CIC</th></tr></thead><tbody><tr><td>Interproton distance restraints</td><td>230</td><td>88</td></tr><tr><td>Intraresidue</td><td>64</td><td>36</td></tr><tr><td>Sequential</td><td>75</td><td>45</td></tr><tr><td>Medium range (i – j &lt; 5)</td><td>79</td><td>7</td></tr><tr><td>Long range (i – j ≥ 5)</td><td>12</td><td>0</td></tr><tr><td>Dihedral-angle restraints</td><td>30</td><td>15</td></tr><tr><td colspan="3"><strong>R.m.s. deviations from the mean coordinate structure (Å)</strong></td></tr><tr><td>Backbone atoms</td><td>0.79 +/- 0.3</td><td>2.06 +/- 0.73</td></tr><tr><td>All heavy atoms</td><td>1.11 +/- 0.22</td><td>2.97 +/- 0.69</td></tr><tr><td colspan="3"><strong>Ramachandran statistics</strong></td></tr><tr><td>% in most favoured region</td><td>82.6%</td><td>62.2%</td></tr><tr><td>% in additionally allowed region</td><td>17.4%</td><td>33.7%</td></tr></tbody></table>

### 3. Discussion

α-conotoxin CIC has been previously found in a proteo-transcriptomic study of the predation-evoked venom of *Conus catus* [12]. Since this toxin exhibited a typical α-conotoxin cysteine pattern -CC-C-C [5] along with an unusual N-terminal extended tail, we decided to investigate the influence of the N-terminal tail on the three-dimensional structure and on the pharmacological properties of the toxin. To this end, we synthesized the globular form (CysI-CysIII, CysII-CysIV) of the α-conotoxin CIC as well as a mutant variant named Δ-CIC in which the first six residues (Ala1-Thr6) were removed. Considering that the other known bioactive 4/7 α-conotoxins [5] mainly display the “native” globular fold, a regioselective folding strategy was applied.
So far, α-GID [10] is the only described 4/7 α-conotoxin with an extended N-terminal tail. α-GID was isolated using assay-directed fractionation of *Conus geographus* crude venom and is a potent blocker of α3β2, α7 (low nanomolar IC₅₀, Table 1) and α4β2 nAChR subtypes (IC₅₀ 152 nM, Table 1). It is noteworthy that the deletion of the N-terminal sequence of GID (Δ-1-4) leads to a significant loss of potency at the α4β2 subtype [10]. However, unlike α-GID, α-CIC showed no inhibition of α4β2 nAChR subtypes at concentrations up to 10 µM. Moreover, the structure of the N-terminal tail of CIC was found to be well-defined, which is in contrast to the disordered N-terminal tail of conotoxin GID [10] (Figure 4A).

<figure><img src="image_8.png" /><figcaption>**Figure 4.** Superposition of CIC with GID and Δ-CIC. (A). Superimposition of the 20 lowest energy states of CIC (red) and GID (PDB: 1MTQ, mauve) over backbone atoms of residues Cys7-Cys21 (CIC numbering). Only the backbones are represented in ribbon format. (B). Superposition of the lowest energy state of CIC (red) and Δ-CIC (blue) over backbone atoms of residues Cys7-Cys21 (CIC numbering). The backbones are shown in ribbon format and the side-chains in stick format.</figcaption></figure>

In addition to its N-terminal tail, α-CIC displays high sequence similarity to α-
conotoxin MII, including the conservation of some critical residues (Figure 1A) that
have been described to be responsible for its low nanomolar activity at α3β2* and α7
nAChRs [14,16,19]. Everhart et al. [18] performed an Ala-scan of α-conotoxin MII and
showed that Asn5, Pro6 and His12 play a major role in α-conotoxin binding, probably via
Asn5 and His12 electrostatic interactions with β2E61 and β2D169, as suggested by molec-
ular modeling. Despite displaying all the sequence features required for the inhibitory
potency and high sequence similarity with α-conotoxin MII, CIC and Δ-CIC were found to
be ~1000-fold less potent at α3β2 and α6α3β2β3 nAChRs than MII (Table 1). This potency
drop most likely arises from slight structural differences between MII and CIC/Δ-CIC
that weaken and/or prevent the critical interactions between the toxin and the nAChRs.
To further assess the potency and selectivity profile of CIC and Δ-CIC, we have tested
them at other common nAChR subunit combinations such as rat α4β4, α3β4, α2β2, α2β4
and (α1)2β1δγ subtypes as well as the human α9α10 subtype. Interestingly, no inhibition
was detected at any of these receptors at concentrations up to 10 µM, highlighting the
high selectivity profile of CIC and Δ-CIC for α3β2 and α6/α3β2β3 nAChRs. Moreover,
our result suggests that there is no influence of the N-terminal tail on the activity at α3β2
and α6/α3β2β3 nAChRs since CIC and Δ-CIC display quasi-similar inhibition constants
(Table 1, Figure 2). Thus, we suggest that the N-terminal tail could serve as a chemical
platform for bioconjugation and that CIC bioconjugates could be developed into valuable
pharmacological tools to probe α3β2* nAChRs.

While the N-terminal tail has no influence on CIC potency, it clearly plays two major
roles at the structural level: (i) decrease of flexibility and (ii) stabilization of secondary
structure. Indeed, Figure 3 clearly shows that the NMR structure of Δ-CIC is less defined
than that of CIC, as highlighted by the RMSD values (Table 2). Moreover, the N-terminal tail is associated with an additional 3¹⁰ helix from residues Thr6 to Ser9, which contains the first two cysteine residues. This result suggests that the N-terminal tail of CIC plays a major role in the stabilization of the global structure. Additionally, the superposition of CIC and Δ-CIC reveals a major structural deviation of Δ-CIC (compared to CIC) in the C-terminal region (Figure 4B). Whereas the calculated RMSD value is 0.88 Å from residues Cys7 to Gln14 (CIC numbering), this value greatly increases to 6.29 Å from residues Cys7 to Cys21, i.e., when the C-terminal region is included. Interestingly, the C-terminal region is not only less structured but is in a different orientation compared to CIC, which could be attributed to the absence of the additional first helix (residues Thr6-Ser9), forcing the CysII-CysIV bridge into a different position compared to the CIC conotoxin.

Overall, the role of the N-terminal tail in α-conotoxins remains poorly understood. During the writing of this article, a new conotoxin, Pl168, was identified in the transcriptome of *Conus planorbis*, which shows an unusual 4/8 loop framework. Pl168 also displays an extended N-terminal tail comprising five amino acids but did not show inhibitory potency on a range of nAChRs, Ca²⁺ and Na⁺ channels [20]. It cannot be excluded that these N-terminally extended conotoxins (Pl168 and CIC) target a different class of receptors or that they are designed to be effective on cone snail prey receptors, which likely display structural differences to mammalian receptors.

# 4. Materials and Methods

## 4.1. *Abbreviations*

ACh, Acetylcholine; Acm, acetamidomethyl; ACN, acetonitrile; Boc, tert-butoxycarbonyl; DCM, dichloromethane; DIPEA, diisopropylethylamine; DMF, N,N'-dimethylformamide; DTP, 2,2'-dithiopyridine; ESI-MS, electrospray ionization mass spectrometry; Fmoc, fluorenylmethoxycarbonyl; HATU, 1[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate; LC/MS, liquid chromatography/mass spectrometry; MeOH, methanol; nAChR, nicotinic acetylcholine receptor; NMR, nuclear magnetic resonance; Pbf, pentamethyl-dihydrobenzofuran-5-sulfonyl; RP-HPLC, reversed-phase high performance liquid chromatography; SPPS, solid-phase peptide synthesis; t-Bu, tert-butyl; TFA, trifluoroacetic acid; TIS, triisopropylsilane; Tris, 2-Amino-2-(hydroxymethyl)propane-1,3-diol; Trt, trityl; UV, ultra-violet.

## 4.2. *Chemical Synthesis*

DMF, DIPEA, ACN, TIS, TFA, piperidine and all other reagents were obtained from Sigma-Aldrich (Saint-Louis, MI, USA) or Merck (Darmstadt, Germany) and were used as supplied. Fmoc (L) amino acid derivatives and HATU were purchased from Iris Biotech (Marktredwitz, Germany). PS-2-Chlorotrityl chloride resin (100-200 mesh, 1.6 mmol/g) was purchased from Iris Biotech (Marktredwitz, Germany). The following side-chain protecting groups were used: Trt for Asn, II-IV Cys, His and Gln; tBu for Ser, Thr and Asp; and Acm for I-III Cys. Peptides were manually synthesized using the Fmoc-based solid-phase peptide synthesis technique as already described elsewhere [15]. All Fmoc amino acids and HATU were dissolved in DMF to reach 0.5 M. The first amino acid was coupled onto the resin for 6 h in a 1/1 (v/v) mix of DMF and DCM, with a 2.5-fold excess of amino acid and 5-fold excess of DIPEA followed by addition of methanol and further mixing for 15 min to cap any remaining reactive functionalities on the resin. The resin was washed with DMF, DCM, MeOH, and DMF. Fmoc deprotection was carried out with piperidine in DMF (1/2 v/v) twice for 3 min. Subsequent amino acids were coupled onto 0.1 mmol of prepared resin (determined loading value 0.73 mmol/g) twice for 10 min using an amino acid/HATU/DIPEA ratio of 5:5:10 relative to resin loading. DMF was used for resin washing between deprotection and coupling steps. After chain assembly was complete, the terminal Fmoc group was removed and the resin washed with DMF and DCM. Side-chain (except Acm) deprotection and cleavage from the resin was carried out by adding 10 mL of TFA/TIS/H₂O (95/2.5/2.5 v/v/v) and stirring the mixture for
2.5 h at room temperature. Crude peptides were purified by preparative RP-HPLC and pure fractions were combined and freeze-dried. A two-step oxidation procedure was then carried out. The first disulfide bridge was formed between the free cysteine residues CysII-CysIV by dissolving the peptide at 0.2 mM in 50 mM Tris-HCl buffer adjusted to pH 8 and adding dropwise 7 equivalents of DTP at 10 mM in MeOH. When the reaction was complete, the reaction mixture was acidified to pH 3 and loaded onto preparative RP-HPLC and pure fractions were combined. The second disulfide bridge (CysI-CysIII) was formed by deprotection/oxidation of the Acm protecting group directly on the combined pure fractions of the mono-bridged intermediates by treatment with 20 equivalents of 10 mM iodine in H₂O/TFA/ACN (78/2/20 v/v/v). When the reaction was complete, the reaction mixture was quenched with 20 mM ascorbic acid until total discoloration of the solution, acidified and purified by preparative RP-HPLC. The combined pure fractions were freeze-dried, and their purity was confirmed by LC/ESI-MS. CIC and Δ-CIC peptides were obtained with 3.2 and 3.1% yields (from resin loading), respectively (purity >95% estimated from LC/ESI-MS). The peptide content was estimated (from amino acid analysis) at 60% from dry weight.

### 4.3. *Mass Spectrometry*

#### 4.3.1. Solvents Used for LC/MS Were of HPLC Grade

Intermediate peptides were characterized using an LC/MS system consisting of an Alliance 2695 HPLC coupled to a ZQ mass spectrometer (Waters, Corp., Milford, MA, USA) fitted with an electrospray ionization source operated in the positive mode (ESI+) and a quadrupole mass analyzer. All the analyses were carried out using a Chromolith (Fontenay sous Bois, France) HighResolution RP-18e (4.6 × 25 mm, 15 nm pore, 1.15 µm particle size, flow rate 3.0 mL/min) column. A flow rate of 3 mL/min and a gradient of 0–100% B over 2.5 min for routine analyses and 0–30% B over 30 min for quality control of pure products were used. Eluent A was water/0.1% HCO₂H, and eluent B consisted of acetonitrile/0.1% HCO₂H. UV detection was performed at 214 nm. Electrospray mass spectra were acquired at a solvent flow rate of 200 µL/min. Nitrogen was used for both the nebulizing and drying gas. The data were obtained in a scan mode ranging from 100 to 1000 m/z or 250 to 1500 m/z in 0.7 s intervals.

Folded peptides were characterized using a Synapt G2-S high-resolution MS system (Waters, Corp., Milford, MA, USA) equipped with an ESI source and a hybrid Q-TOF mass analyzer configuration. Chromatographic separation was carried out at a flow rate of 0.4 mL/min on an Acquity H-Class ultrahigh performance liquid chromatography (UPLC) system (Waters, Corp., Milford, MA, USA) equipped with a Kinetex C18 100 Å column (100 mm × 2.1 mm, 2.6 µm particle size) from Phenomenex (France). The mobile phase consisted of water (solvent A) and ACN (solvent B) with both phases acidified by 0.1% (v/v) formic acid. Mass spectra were acquired in the positive ionization mode.

#### 4.3.2. Preparative RP-HPLC

Preparative RP-HPLC was run on a Gilson PLC 2250 Purification system (Villiers le Bel, France) instrument using a preparative column (Waters DeltaPak C18 Radial-Pak Cartridge, 100 Å, 40 × 100 mm, 15 µm particle size, flow rate 50.0 mL/min). Buffer A was 0.1% TFA in water, and buffer B was 0.1% TFA in acetonitrile.

### 4.4. *Electrophysiology*

Functional experiments were performed as described previously [15]. Briefly, plasmids encoding the respective nAChR subunits (rat α2, α3, α4, α6, β2, β4 nAChRs provided by Jim Patrick (Baylor College of Medicine, Houston, TX, USA) and subcloned in pNKS2; rat α1, β1, γ, δ in pSPOoD provided by Veit Witzemann (MPI for Medical Research, Heidelberg, Germany); human α9 and α10 in pT7TS provided by David Adams (Illawara Health and Medical Research Institute, Wollongong University, Wollongong, Australia); α6/α3 chimera generated in pNKS [15,16,21] were linearized and cRNA synthesized using
the mMessageMachine kit (Invitrogen, ThermoFisher Scientific, Waltham, MA, USA). Fifty nanoliters of cRNA (0.1–0.5 µg/µL) was injected per oocyte (EcoCyte Bioscience (Dortmund, Germany) or a gift from Prof. Luis Pardo (MPI of Experimental Medicine, Göttingen, Germany) with a subunit ratio of 1:1 for α3β2, α3β4, α2β2, α2β4, α4β4, 5:1 for α4β2, 3:1 for α9β10 and 1:1:1 for α6/α3β2β3. Oocytes were stored at 16 °C in sterile-filtered ND96 containing 5 µg/ml gentamicin.

After 1–4 days, two-electrode voltage clamp recordings were performed at –70 mV with a Turbo Tec 05X Amplifier (npi electronic, Tamm, Germany) and CellWorks software. Electrode resistances were less than 1 MΩ, and currents were filtered at 200 Hz and digitized at 400 Hz. The recording solution (ND115 for α9β10, ND96 in all other cases) with or without ACh was automatically applied via a custom-made magnetic valve system combined with a manifold mounted closely above the oocyte, thus allowing a fast (<300 ms) and reproducible solution exchange. Toxins were applied manually in the 50-µl measuring chamber and preincubated for 3 min. Agonist pulses (2s) were applied in 4-min intervals. Current responses were normalized to control responses before toxin application. GraphPad Prism (version 9.0) was used for data analysis, and a four-parameter logistic fit (Hill-fit) with plateaus constrained to 100% and 0% was used to generate dose–response curves. Oocytes from at least two frogs were used for each experiment.

### 4.5. NMR Structure Determination

NMR spectra were acquired using a Bruker 600 MHz AVANCE III NMR spectrometer (Bruker, Karlsruhe, Germany) equipped with a cryoprobe. Lyophilized synthetic peptides (~1.5–2 mg) were dissolved in 90% H₂O/10% D₂O, and 2D ¹H-¹H TOCSY, ¹H-¹H NOESY, ¹H-¹H DQF-COSY, ¹H-¹⁵N HSQC, and ¹H-¹³C HSQC spectra were recorded using standard Bruker pulse sequences with excitation sculpting for solvent suppression. All spectra were acquired at 290 K with an interscan delay of 1 s. A mixing time of 200–250 ms was used when acquiring NOESY spectra, and isotropic mixing periods of 80 ms for TOCSY spectra. Spectra were processed using Topspin v3.6.1 (Bruker, Billerica, MA, USA) and assigned manually in CcpNmr V2 [22]. An ensemble of structures was calculated using CYANA [23] including torsion-angle restraints generated by TALOS+ [24]. Final structures were visualized using MOLMOL [25] PyMol (The PyMOL Molecular Graphics System, Version 2.0 Schroödinger, LLC., New York, NY, USA) and UCSF Chimera 4.1 [26].

**Author Contributions:** Conceptualization, J.G. and S.D.; methodology, J.G., Y.H., D.T.W. and N.L.D.; data acquisition, J.G., Y.H. and E.R.J.E.; validation, D.T.W., N.L.D., A.N. and S.D.; formal analysis and data curation, J.G., Y.H., E.R.J.E., N.L.D. and D.T.W.; writing—original draft preparation, J.G.; writing—review and editing, all authors; supervision, D.T.W., N.L.D., A.N., C.E. and S.D. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work received financial support from the French Ministry of Higher Education, Research and Innovation (PhD scholarship to J.G.) and a grant from the German Research Foundation (DFG, Research Training Group GRK 2338, P01) to A.N. The James Cook University NMR facility was partially funded by the Australian Research Council (LE160100218). This project was supported by an AITHM Capacity Building Grant (D.W.). The Northcote Trust supports E.R.J.E. with a Northcote Graduate Scholarship.

**Data Availability Statement:** The structures presented in this paper have all been deposited in the Protein Data Bank (PDB) and Biological Magnetic Resonance Bank (BMRB) with the following codes: CIC (PDB: 7LQR) and (BMRB: 30859); Δ-CIC (PDB: 7LQS) and (BMRB: 30860). All remaining data are contained within the article.

**Acknowledgments:** We thank Fiona Mandausch and Pranavkumar Shadamarshan for assistance and Han Shen Tae and David Adams (Illawarra Health and Medical Research Institute, Wollongong University, Australia) for providing nAChR cDNAs.

**Conflicts of Interest:** The authors declare no conflict of interest.
## References

1. Giribaldi, J.; Dutertre, S. α-Conotoxins to explore the molecular, physiological and pathophysiological functions of neuronal nicotinic acetylcholine receptors. *Neurosci. Lett.* **2018**, *679*, 24–34. [CrossRef]

2. Puillandre, N.; Duda, T.F.; Meyer, C.P.; Olivera, B.M.; Bouchet, P. One, four or 100 genera? A new classification of the cone snails. *J. Molluscan Stud.* **2015**, *81*, 1–23. [CrossRef] [PubMed]

3. Dutertre, S.; Jin, A.-H.; Vetter, I.; Hamilton, B.; Sunagar, K.; Lavergne, V.; Dutertre, V.; Fry, B.G.; Antunes, A.; Venter, D.J.; et al. Evolution of separate predation- and defence-evoked venoms in carnivorous cone snails. *Nat. Commun.* **2014**, *5*, 3521. [CrossRef] [PubMed]

4. Davis, J.; Jones, A.; Lewis, R.J. Remarkable inter- and intra-species complexity of conotoxins revealed by LC/MS. *Peptides* **2009**, *30*, 1222–1227. [CrossRef] [PubMed]

5. Akondi, K.B.; Muttenthaler, M.; Dutertre, S.; Kaas, Q.; Craik, D.J.; Lewis, R.J.; Alewood, P.F. Discovery, Synthesis, and Structure–Activity Relationships of Conotoxins. *Chem. Rev.* **2014**, *114*, 5815–5847. [CrossRef] [PubMed]

6. Lewis, R.J.; Garcia, M.L. Therapeutic potential of venom peptides. *Nat. Rev. Drug Discov.* **2003**, *2*, 790–802. [CrossRef] [PubMed]

7. El Hamdaoui, Y.; Wu, X.; Clark, R.J.; Giribaldi, J.; Anangi, R.; Craik, D.J.; King, G.F.; Dutertre, S.; Kaas, Q.; Herzig, V.; et al. Periplasmic Expression of 4/7 α-Conotoxin TxIA Analogs in E. coli Favors Ribbon Isomer Formation—Suggestion of a Binding Mode at the α7 nAChR. *Front. Pharmacol.* **2019**, *10*, 577. [CrossRef]

8. Kaas, Q.; Westermann, J.-C.; Halai, R.; Wang, C.K.L.; Craik, D.J. ConoServer, a database for conopeptide sequences and structures. *Bioinformatics* **2008**, *24*, 445–446. [CrossRef]

9. Kaas, Q.; Yu, R.; Jin, A.-H.; Dutertre, S.; Craik, D.J. ConoServer: Updated content, knowledge, and discovery tools in the conopeptide database. *Nucleic Acids Res.* **2011**, *40*, D325–D330. [CrossRef]

10. Nicke, A.; Loughnan, M.L.; Millard, E.L.; Alewood, P.F.; Adams, D.J.; Daly, N.L.; Craik, D.J.; Lewis, R.J. Isolation, Structure, and Activity of GID, a Novel α4/7-Conotoxin with an Extended N-terminal Sequence. *J. Biol. Chem.* **2003**, *278*, 3137–3144. [CrossRef] [PubMed]

11. Cordero-Erausquin, M.; Marubio, L.M.; Klink, R.; Changeux, J.-P. Nicotinic receptor function: New perspectives from knockout mice. *Trends Pharmacol. Sci.* **2000**, *21*, 211–217. [CrossRef]

12. Himaya, S.W.A.; Jin, A.-H.; Dutertre, S.; Giacomotto, J.; Mohialdeen, H.; Vetter, I.; Alewood, P.F.; Lewis, R.J. Comparative Venomics Reveals the Complex Prey Capture Strategy of the Piscivorous Cone Snail Conus catus. *J. Proteome Res.* **2015**, *14*, 4372–4381. [CrossRef] [PubMed]

13. McIntosh, J.M.; Plazas, P.V.; Watkins, M.; Gomez-Casati, M.E.; Olivera, B.M.; Elgoyhen, A.B. A Novel α-Conotoxin, PeIA, Cloned from *Conus pergrandis*, Discriminates between Rat α9α10 and α7 Nicotinic Cholinergic Receptors. *J. Biol. Chem.* **2005**, *280*, 30107–30112. [CrossRef] [PubMed]

14. Cartier, G.E.; Yoshikami, D.; Gray, W.R.; Luo, S.; Olivera, B.M.; McIntosh, J.M. A New α-Conotoxin Which Targets α3β2 Nicotinic Acetylcholine Receptors. *J. Biol. Chem.* **1996**, *271*, 7522–7528. [CrossRef]

15. Giribaldi, J.; Wilson, D.; Nicke, A.; El Hamdaoui, Y.; Laconde, G.; Faucherre, A.; Moha, O.; Maati, H.; Daly, N.; Enjalbal, C.; et al. Synthesis, Structure and Biological Activity of CIA and CIB, Two α-Conotoxins from the Predation-Evoked Venom of *Conus catus*. *Toxins* **2018**, *10*, 222. [CrossRef]

16. McIntosh, J.M.; Azam, L.; Staheli, S.; Dowell, C.; Lindstrom, J.M.; Kuryatov, A.; Garrett, J.E.; Marks, M.J.; Whiteaker, P. Analogs of α-Conotoxin MII Are Selective for α6-Containing Nicotinic Acetylcholine Receptors. *Mol. Pharmacol.* **2004**, *65*, 944–952. [CrossRef] [PubMed]

17. Klimis, H.; Adams, D.J.; Callaghan, B.; Nevin, S.; Alewood, P.F.; Vaughan, C.W.; Mozar, C.A.; Christie, M.J. A novel mechanism of inhibition of high-voltage activated calcium channels by α-conotoxins contributes to relief of nerve injury-induced neuropathic pain. *Pain* **2011**, *152*, 259–266. [CrossRef]

18. Everhart, D.; Cartier, G.E.; Malhotra, A.; Gomes, A.V.; McIntosh, J.M.; Luetje, C.W. Determinants of Potency on α-Conotoxin MII, a Peptide Antagonist of Neuronal Nicotinic Receptors. *Biochemistry* **2004**, *43*, 2732–2737. [CrossRef] [PubMed]

19. Dutertre, S.; Nicke, A.; Lewis, R.J. β2 Subunit Contribution to 4/7 α-Conotoxin Binding to the Nicotinic Acetylcholine Receptor. *J. Biol. Chem.* **2005**, *280*, 30460–30468. [CrossRef] [PubMed]

20. Wilson, D.T.; Bansal, P.S.; Carter, D.A.; Vetter, I.; Nicke, A.; Dutertre, S.; Daly, N.L. Characterisation of a Novel A-Superfamily Conotoxin. *Biomedicines* **2020**, *8*, 128. [CrossRef]

21. Kuryatov, A.; Olale, F.; Cooper, J.; Choi, C.; Lindström, J. Human α6 AChR subtypes: Subunit composition, assembly, and pharmacological responses. *Neuropharmacology* **2000**, *39*, 2570–2590. [CrossRef]

22. Skinner, S.P.; Fogh, R.H.; Boucher, W.; Ragan, T.J.; Mureddu, L.G.; Vuister, G.W. CcpNmr AnalysisAssign: A flexible platform for integrated NMR analysis. *J. Biomol. NMR* **2016**, *66*, 111–124. [CrossRef] [PubMed]

23. Güntert, P. Automated NMR Structure Calculation with CYANA. In *Protein NMR Techniques*; Humana Press: Totowa, NJ, USA, 2004; pp. 353–378.
24. Shen, Y.; Delaglio, F.; Cornilescu, G.; Bax, A. TALOS+: A hybrid method for predicting protein backbone torsion angles from NMR chemical shifts. *J. Biomol. NMR* **2009**, *44*, 213–223. [CrossRef] [PubMed]

25. Koradi, R.; Billeter, M.; Wüthrich, K. MOLMOL: A program for display and analysis of macromolecular structures. *J. Mol. Graph. 1996*, *14*, 51–55. [CrossRef]

26. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera? A visualization system for exploratory research and analysis. *J. Comput. Chem.* **2004**, *25*, 1605–1612. [CrossRef] [PubMed]